Reaction equation
[C:1]([O:5][C:6]([N:8]1[CH2:12][CH2:11][CH2:10][CH:9]1[C:13]1[NH:14][C:15]([C:18]2[CH:31]=[CH:30][C:29]3[C:28]4[C:23](=[CH:24][C:25]([C:32]5[NH:33][C:34]([CH:37]6[CH2:41][CH2:40][CH2:39][N:38]6[C:42]([O:44][C:45]([CH3:48])([CH3:47])[CH3:46])=[O:43])=[N:35][CH:36]=5)=[CH:26][CH:27]=4)[CH2:22]C[C:20]=3[CH:19]=2)=[CH:16][N:17]=1)=[O:7])([CH3:4])([CH3:3])[CH3:2].CC1(C)C(C)(C)OB(C2C=CC3C4C(=CC(B5OC(C)(C)C(C)(C)O5)=CC=4)CC=3C=2)O1>>[C:45]([O:44][C:42]([N:38]1[CH2:39][CH2:40][CH2:41][CH:37]1[C:34]1[NH:33][C:32]([C:25]2[CH:26]=[CH:27][C:28]3[C:29]4[C:30](=[CH:31][C:18]([C:15]5[NH:14][C:13]([CH:9]6[CH2:10][CH2:11][CH2:12][N:8]6[C:6]([O:5][C:1]([CH3:3])([CH3:4])[CH3:2])=[O:7])=[N:17][CH:16]=5)=[CH:19][CH:20]=4)[CH2:22][C:23]=3[CH:24]=2)=[CH:36][N:35]=1)=[O:43])([CH3:47])([CH3:46])[CH3:48]Participants
3
Reactant 2
Product 1
Procedure
Followed the procedure used to prepare compound 2-(5-{7-[2-(1-Boc-pyrrolidin-2-yl)-3H-imidazol-4-yl]-9,10-dihydro-phenanthren-2-yl}-1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester, except that 4,4,5,5-tetramethyl-2-[7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-9H-fluoren-2-yl]-[1,3,2]dioxaborolane was used instead of 4,4,5,5-tetramethyl-2-[7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-9,10-dihydro-phenanthren-2-yl]-[1,3,2]dioxaborolane. m/z 637.1 (M+H)+.
Sources & evidence
- ORD record
- ord-e879ef83efe24ba39e8304a8329e9ddd
- Source dataset
- uspto-grants-2014_03
- Patent number
- US08669234B2
Linked notes
Loading…